Home > Boards > US OTC > Biotechs >

Regen BioPharma Inc (RGBP)

Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, Bigfootbud, pumper_stumper, Carter, Huggy Bear, joe botts
Search This Board: 
Last Post: 5/24/2022 12:59:17 AM - Followers: 1122 - Board type: Free - Posts Today: 1


Regen BioPharma 
Followers: 388 Since 10/10/19

 0.000x  Ticker Symbol: RGBP 
Last iBox update 08/09/2020 4PM by CrazyKar123



Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation

All other Regen BioPharma News


Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.

Telephone: (619) 702-1404
Fax: (619) 330-2328

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).


Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD


Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 



Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia


Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia

Image result for cbd


Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease


SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."



Always research for yourself BEFORE you buy in the OTC !!!!

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RGBP News: Current Report Filing (8-k) 05/17/2022 06:08:02 AM
RGBP News: Quarterly Report (10-q) 04/21/2022 04:36:58 AM
RGBP News: Current Report Filing (8-k) 03/18/2022 12:26:29 PM
RGBP News: Current Report Filing (8-k) 02/18/2022 08:19:45 AM
RGBP News: Regen BioPharma to start mRNA anti-cancer vaccine development program 02/11/2022 04:40:56 AM
#106600  Sticky Note 1 BILLION new shares authorized, necessary, due to pumper_stumper 04/03/22 05:39:30 PM
#105377  Sticky Note Great news: Regen BioPharma, Inc. Announces Program to sharky 03/10/22 08:27:11 AM
#41420  Sticky Note RGBP/Zander patents... gotinearly 03/29/21 09:43:29 AM
#108669   Glad to see you back 29YI. Sure Trish0949 05/24/22 12:59:17 AM
#108668   Botts.. hope you and your loved ones are moondogaz 05/23/22 11:39:26 PM
#108667   This was to be in dollar land months ago. rockie101 05/23/22 11:24:58 PM
#108666   I could handle that bud. BDEZ 05/23/22 10:50:30 PM
#108665   Guess we'll know soon enough. Seems like a Jack Torrance 05/23/22 10:11:33 PM
#108664   Wow wow weee joe botts 05/23/22 09:47:33 PM
#108663   Ok thank you joe botts 05/23/22 09:45:08 PM
#108660   That’s a fact The Law (f/k/a emz) 05/23/22 08:45:59 PM
#108659   Correct, charts and technicals have very little to The Law (f/k/a emz) 05/23/22 08:45:21 PM
#108657   Right BDEZ, hoping we can get back to JMC$ 05/23/22 07:33:24 PM
#108656   LOL Seeing that the crowd wisdom here only thinks Musical Shares 05/23/22 07:24:51 PM
#108655   Drop continues till we hit $0.0016 Then will wait Elgordo84 05/23/22 07:05:43 PM
#108654   Whoa...wait...you truly don't think this is due to SidVicious 05/23/22 07:04:34 PM
#108653   Technical buying doesn't account for this nearly 100% Jack Torrance 05/23/22 06:58:27 PM
#108652   The answers to why this jumped today are Musical Shares 05/23/22 06:52:46 PM
#108651   Chart JAM 05/23/22 06:26:08 PM
#108650   That's awesome considering all of the averaging down SidVicious 05/23/22 06:00:59 PM
#108649   I need to average all yhe way down Fredric 05/23/22 05:57:07 PM
#108648   What in Sam blazin hills is going on here??? Fredric 05/23/22 05:46:10 PM
#108646   LOL! I’m only up138k today on my RGBP Shares, 29YEARINVESTOR 05/23/22 05:41:08 PM
#108645   When will this get over 1 cent? SidVicious 05/23/22 05:28:43 PM
#108644   Naked shorters aka MM are going to destroy SidVicious 05/23/22 05:27:59 PM
#108643   What's the math about today's % appreciation from raja48185 05/23/22 05:27:22 PM
#108642   How about Naked short MM’s covering before the 29YEARINVESTOR 05/23/22 05:26:09 PM
#108641   About time right JMC? Hope we see a BDEZ 05/23/22 05:14:59 PM
#108640   emz, RGBP closed up almost 40% today :-) JMC$ 05/23/22 04:27:04 PM
#108639   Someone sure did! StayHumble 05/23/22 04:13:28 PM
#108638   Yea how bout dat joe botts 05/23/22 04:05:10 PM
#108637   Many buyers like you must have bought some archilles 05/23/22 03:53:58 PM
#108636   How about maybe debt holder took a break pumper_stumper 05/23/22 03:53:00 PM
#108635   Anyone knows what's driving this recent rise? No Jack Torrance 05/23/22 03:44:48 PM
#108634   RGBP Nice day here Capitalvaluetrade 05/23/22 03:42:59 PM
#108633   MMs maybe ready to make this run, they jaiguruji7 05/23/22 03:42:52 PM
#108632   ThugMuffin......... You brought some real growth to sherman106 05/23/22 03:35:22 PM
#108631   Old hat? richme 05/23/22 03:32:20 PM
#108630   RGBP lets roll :o) DEMDOTS 05/23/22 03:07:59 PM
#108629   I’ve been holding this a long time, what’s MoneyLover1010 05/23/22 02:47:52 PM
#108628   Me too,I added a Milli in the high 3s art35 05/23/22 02:43:52 PM
#108627   I'm pretty happy I added the last few weeks... Johnnie Ringo 05/23/22 02:29:26 PM
#108622   Getting closer to something here... Carter 05/23/22 01:47:34 PM
#108619   Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: 29YEARINVESTOR 05/23/22 01:40:54 PM
#108618   Right, because that's how all penny stock trade! SidVicious 05/23/22 01:37:06 PM
#108616   $RGBP just an example I bought ENZC at HighYieldStocks 05/23/22 01:15:55 PM
#108615   $RGBP ... this board is full of longs, HighYieldStocks 05/23/22 01:14:03 PM
#108614   FOMO is about to kick in. Preferred shares HighYieldStocks 05/23/22 01:13:22 PM
#108613   4 Cancer Treatment related Patents Granted in the 29YEARINVESTOR 05/23/22 01:12:06 PM
#108612   There goes thatn911911 call again on the MMs!! stokbrokin 05/23/22 01:11:38 PM
#108611   Momentum looks strong, Macd BREAKING thru the Zero Line...... sherman106 05/23/22 12:52:32 PM
#108610   SQUUEEEZZZEE the Shorts and Devil´s Advocat aka MM´s ...GOOOOOOOOOO HighYieldStocks 05/23/22 12:51:07 PM
#108609   Ohhh thank ya! joe botts 05/23/22 12:29:57 PM
Consent Preferences